[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

632.P1.45 Chronic Myeloid Leukemia - Therapy: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 4, 2010: 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
Frequency of Complete Molecular Response In Chronic Myeloid Leukemia Patients In Real Life Practice

Matthieu Decamp1*, Dina Istasi, MBBCH, MD, CES2, Atchroue Johnsonansah3*, Oumedaly Reman, MD4, Xavier Levaltier5*, Christophe Fruchart, MD6*, Vincent Launay, MD7*, Seyeffedine Kadi, MD8* and Xavier Troussard, MD, PhD9*

1Laboratoire d'Hématologie, Chu Côte de Nacre, Caen, France
2'Cote de Nacre' Hematology Laboratory, Centre Hospitalier Universitaire, Caen, France
3Hématologie Clinique, Chu Côte de Nacre, Caen, France
4CHU Caen, Université Caen, Caen, France
5Hematologie, Clinique du Parc, Caen, France
6Hematology, Centre François Baclesse, Caen
7Medecine C, Centre Hospitalier du Cotentin, Cherbourg, France
8Hopital de jour Onco-hématologie, St Hositalier Memorial de St Lô, ST Lô, France
9Laboratoire d'Hématologie, CHU CAEN, CAEN Cedex 5, France

Poster Board Number: I-207
Potential Pitfalls In Quantitative Real-Time PCR for Molecular Monitoring of BCR-ABL In the Management of CML

Hanfang Zhang, MD, PhD1*, Niren Patel, MBBS1*, Ferdane Kutlar, MD1*, Anand P. Jillella, MD2, Celalettin Ustun, MD3*, Leigh G Wells, MSN, RN, FNP-BC1*, Betsy Clair1* and Abdullah Kutlar, MD1

1Sickle Cell Center, Medical College of Georgia, Augusta, GA
2Medical College of Georgia, Augusta, GA
3 Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Poster Board Number: I-208
Imatinib In Very Elderly CML Patients: What Can We Achieve?

Roberto Latagliata1*, Dario Ferrero2*, Francesco Cavazzini3, Malgorzata Monika Trawinska4*, Massimo Breccia, MD5*, Mario Annunziata6*, Fabio Stagno, MD7*, Mario Tiribelli8*, Gianni Binotto9*, Elena Crisà2*, Pellegrino Musto, MD10*, Antonella Gozzini11*, Laura Cavalli12*, Raffaele Porrini13*, Michele Cedrone14*, Antonella Russo Rossi15*, Patrizia Pregno16*, Mauro Endri17*, Antonio Spadea18*, Gianfranco Giglio19*, Federica Sorà20*, Sergio Storti21, Ada M D'Addosio22*, Giovanna Rege Cambrin23*, Luigiana Luciano24*, Elisabetta Abruzzese25* and Giuliana Alimena26*

1Dept. of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy
2Division of Hematology, A.O.U. San Giovanni Battista, Univesity of Torino, Turin, Italy
3Haematology Dept., University of Ferrara, Ferrara, Italy
4Department of Hematology, S. Eugenio Hospital, S. Eugenio Hospital, Rome, Italy
5Department of Cellular Biotechnologies and Hematology, University of Rome “La Sapienza”, Rome, Italy
6Ospedale Cardarelli, Napoli
7University of Catania, Catania, Italy
8Chair of Hematology, University of Udine, Udine, Italy
9Hematology, University of Padua, Padua, Italy
10Onco-Hematology, Department of Hematology, Scientific Institute of Research and Cure, Reference Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy
11Hematology Department, Careggi University Hospital, Firenze, Italy
12Hematology, University of Perugia, Perugia, Italy
13Hematology, Sant'Andrea Hospital, Sapienza University, Rome, Italy
14Hematology, S.Giovanni Addolorata Hospital, Roma, Italy
15University of Bari, Hematology, Bari, Italy
16Chair of Haematology, University of Torino, Torino
17Transplant Unit, Hematology, Cremona, Cremona, Italy
18Hematology, IFO, Rome, Italy
19Hematology, Campobasso, Italy
20Hematology, Policlinico A Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
21Istituto di Ematologia- Campobasso, Roma, Italy
22Hematology, Villa San Pietro Hospital, Rome, Italy
23Dept. of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
24University of Napoli, Napoli
25Department of Hematology, S. Eugenio Hospital, Rome, Italy
26Department of Cellular Biotechnologies and Hematology, University of Rome "La Sapienza", Rome, Italy

Poster Board Number: I-209
BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis

Fausto Castagnetti1*, Gabriele Gugliotta1*, Francesca Palandri1*, Massimo Breccia2*, Giorgina Specchia3*, Elisabetta Abruzzese4*, Tamara Intermesoli5*, Adele Capucci6*, Bruno Martino7*, Fabio Stagno8*, Patrizia Pregno9*, Marilina Amabile1*, Simona Soverini1*, Nicoletta Testoni1*, Giuliana Alimena2*, Giovanni Martinelli1, Fabrizio Pane10*, Giuseppe Saglio11, Michele Baccarani1* and Gianantonio Rosti1*

1Department of Hematology/Oncology "Seràgnoli", University of Bologna, Bologna, Italy
2Department of Hematology, "La Sapienza" University, Roma, Italy
3Department of Hematology, University of Bari, Bari, Italy
4Department of Hematology, S. Eugenio Hospital, Rome, Italy
5Haematology Unit, Ospedali Riuniti, Bergamo, Italy
6Haematology Unit, Spedali Civili, Brescia, Italy
7Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
8Department of Hematology, University of Catania, Catania, Italy
9Chair of Haematology, University of Torino, Torino
10CEINGE-Advanced Biotechnology, University of Naples, Napoli, Italy
11Department of Internal Medicine, Az. Ospedaliera San Luigi Gonzaga, University of Turin, Orbassano-Turin, Italy

Poster Board Number: I-210
The Effect of HO-1 on AMN107 In Promoting K562/A02 Apoptosis

Jishi Wang1, Baisheng Chai2*, Cheng Chen2* and Qin Fang3*

1Hematology, Affiliated Hospital of Guiyang Medical College, Guiyang, China
2Hematology, Affiliated Hospital of Guiyang Medical College, Guiyang China, China
3Pharmacy, Affiliated Hospital of Guiyang Medical College, Guiyang China, China

Poster Board Number: I-211
Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML)

Elias Jabbour, MD1, Hagop Kantarjian, MD1, A. Megan Cornelison, MSPA2*, Tapan Kadia, MD1, Mary-Alma Welch, MMSC, BA1*, Lynne V. Abruzzo, MD, PhD3, Jan A. Burger, MD, PhD1, Alessandra Ferrajoli, MD1, Guillermo Garcia-Manero, MD1 and Jorge E. Cortes, MD4

1Leukemia Department, The University Of Texas MD Anderson Cancer Center, Houston, TX
2Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University Of Texas MD Anderson Cancer Center, Houston, TX
4Leukemia Department, University Of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: I-212
Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Ali M Al-Ameri, MD1*, Jorge E. Cortes2, Hagop M. Kantarjian1, Elizabeth Burton3*, Alfonso Quintas-Cardama, MD1, Elias Jabbour, MD4, Xavier Badoux, MD1, Susan O'Brien, MD5 and Gloria Mattiuzzi, MD1

1Leukemia, MD Anderson Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Poster Board Number: I-213
Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD1, Hagop M. Kantarjian2, Jianqin Shan, PhD3*, Elias Jabbour, MD4, Alfonso Quintas-Cardama, MD2, Srdan Verstovsek, MD, PhD5, Farhad Ravandi, MD2, William G. Wierda, MD, PhD5, Susan O'Brien, MD6 and Jorge E. Cortes6

1Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
2Leukemia, MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Poster Board Number: I-214
Adherence to Treatment In Patients with Chronic Myelogenous Leukemia During a 10-Year Time Period: A Medical Record Review

Marianne Ulcickas Yood, DSc, MPH, FISPE1*, Susan A Oliveria, ScD, MPH, FISPE1*, Ishan Hirji, MPH2*, Mark Cziraky, PharmD, FAHA, CLS3* and Catherine Davis2*

1EpiSource, LLC, Newton, MA
2Bristol-Myers Squibb, Wallingford, CT
3HealthCore, Inc., Wilmington, DE

Poster Board Number: I-215
Risk Score at Diagnosis and the Dynamics of Response to TKI Therapy In Chronic Myeloid Leukemia

Tom Lenearts1*, Fausto Castagnetti2*, Arne Traulsen3*, Jorge M Pacheco4*, Gianantonio Rosti5* and David Dingli, M.D., Ph.D.6

1Université Libre de Bruxelles, Brussels, Belgium
2Department of Hematology and Oncology "L. and A. Seragnoli", University of Bologna, Bologna, Italy
3Max Planck Institute, Plon, Germany
4University of Minho, Minho, Portugal
5Department of Hematology/Oncology, University of Bologna, Bologna, Italy
6Division of Hematology, Mayo Clinic, Rochester, MN

Poster Board Number: I-216
Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Luis Felipe Casado1*, Isabel Massague2*, Pilar Giraldo, MD, PhD3, Manuel Perez-Encinas4*, Raquel De Paz, MD5*, Joaquín Martínez-López, MD6*, Guiomar Bautista7*, Santiago Osorio8*, Maria José Requena9*, Luis Palomera10*, Maria Jesús Peñarrubia11*, Carmen Calle12*, Begoña Maestro13* and Juan Luis Steegmann, MD, PhD14

1Servicio de Hematrología, Hospital Virgen de la Salud, Toledo, Spain
2Servicio de Hematrología, Hospital Valle de Hebron, Barcelona, Spain
3MIGUEL SERVET HOSPITAL, Zaragoza, Spain
4Servicio de Hematrología, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
5Hematology, Hospital Universitario La Paz, Madrid, Spain
6Hematology, Hospital 12 de Octubre, Madrid, Spain
7Servicio de Hematrología, Hospital Puerta de Hierro, Madrid, Spain
8Hematology, Hospital General Univ. Gregorio Marañon, Madrid, Spain
9Hematology, Hospital Universitario Severo Ochoa, Leganés
10Hospital Lozano Blesa, Zaragoza, Spain
11Servicio de Hematrología, Hospital Río Ortega, Valladolid, Spain
12Servicio de Hematrología, Hospital General de Ciudad Real, Ciudad Real, Spain
13Registro Español de Investigación y Tratamiento de Leucemia Mieloide Crónica (RELMC), Madrid, Spain
14Dept. of Hematology, Hospital Universitario de la Princesa, Madrid, Spain

Poster Board Number: I-217
Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2nd and 3rd Tyrosine Kinase Inhibitors (TKIs)

Liunan Li, MD*, Hagop Kantarjian, MD, Meng Zhao, MD*, Susan O'Brien, MD, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Elizabeth Burton*, Stefan Faderl, MD, Alessandra Ferrajoli, MD and Jorge E. Cortes, MD

Leukemia, MD Anderson Cancer Center, Houston, TX

Poster Board Number: I-218
The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003-2009

Hana Klamova1*, Daniela Zackova2*, Edgar Faber3*, Katerina Steinerova4*, Michal Karas4*, Eva Demeckova5*, Jaroslava Voglova, MD6*, Ludmila Demitrovicova7*, Elena Tothova8*, Juraj Chudej, MD9*, Imrich Markuljak10*, Tomas Kozak, MD, PhD11*, Eduard Cmunt, M.D., Ph.D.12*, Marie Jarosova3*, Katerina Machova-Polakova13*, Kyra Michalova, PhD14, Ladislav Dusek15*, Jan Muzik, MSci, PhD16*, Martin Mistrik17*, Jiri Mayer, MD, PhD18, Marek Trneny19 and Karel Indrak20*

1Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2Department of Hematology-oncology, University Hospital Brno, Brno, Czech Republic
3Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic
4Department of Hemato-oncology, University Hospital Plzen, Plzen, Czech Republic
5Hematology, Clinic of Hematology and Blood Transfusion, Bratislava, Slovakia
62nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic
7Hematology, University Hospital and Health Centre Bratislava, Bratislava, Slovakia
8Clinic of Haematology and Oncohaematology, University Hospital L. Pasteura, Kosice, Slovakia
9Hematology, Khat 1/0 MFN, Martin, Slovakia
10University Hospital Banska Bystrica, Banska Bystrica, Slovak Republic
11Department of Clinical Hematology, Third Faculty of Medicine, Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic
12First Department. of Medicine, Charles University General Hospital, Prague, Czech Republic, Czech Republic
13Institute of Hematology and Blood Transfusion, Praha, Czech Republic
141st Faculty of Medicine Center of Oncocytogenetics, General Univerity Hospital, Prague, Czech Republic
15Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science of the Masaryk University Brno, Brno, Czech Republic
16Institute of Biostatistic and Analysis, Masaryk University, Brno, Czech Republic
17University Hospital and Health Centre Bratislava, Bratislava, Slovak Republic
18Dept. of Internal Med.-Hematooncology,University Hospital Brno and CEITEC Masaryk University, Brno, Czech Rep., Brno, Czech Republic
191st Dept Medicine, Charles University General Hospital, Prague, Czech Republic
20Department of Hemato-Oncology, University Hospital, Olomouc, Czech Republic

Poster Board Number: I-219
Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients

Hyun-Gyung Goh1*, Dongho Kim1*, Soo-Young Choi1*, Soo-Hyun Kim1*, Jeong Lee1*, Young-Seok Lee1*, Sang-Mi Oh1* and Dong-Wook Kim2

1Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
2Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine , Seoul, South Korea

Poster Board Number: I-220
Is There a Clinical Benefit for Less Than a Complete Cytogenetic Response (CCyR) for Patients (Pts) with Chornic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKI) as Second or Third Line Therapy?

Jorge E. Cortes1, Alfonso Quintas-Cardama, MD2, Elias Jabbour, MD2, Elizabeth Burton3*, Susan O'Brien, MD4, Srdan Verstovsek, MD, PhD5, Marina Konopleva, MD, PhD6, William G. Wierda, MD, PhD5, Gautam Borthakur2, Farhad Ravandi, MD2 and Hagop M. Kantarjian2

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Leukemia, MD Anderson Cancer Center, Houston, TX
3Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX

Poster Board Number: I-221

*signifies non-member of ASH